Antonios Tavernarakis

Antonios Tavernarakis

Auto-generated profile, based on publicly available information

Antonios Tavernarakis

Department of Neurology, Evangelismos General Hospital, Athens, Greece

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2004 in Immunology Letters
Verified
Journal Article
Closed access
MMMaria Michalopoulou
Maria Michalopoulou
CNChryssoula Nikolaou
Chryssoula Nikolaou
ATAntonios Tavernarakis
Antonios Tavernarakis
NANectaria-Malamatina Alexandri
Nectaria-Malamatina Alexandri
MRMichael Rentzos
Michael Rentzos
DVDimitrios Vassilopoulos
Dimitrios Vassilopoulos

1 December 2013 in Epilepsy & Behavior
Verified
Journal Article
Closed access
Panagiotis ZisPanagiotis Zis
Panagiotis Zis
PYParaskevi Yfanti
Paraskevi Yfanti
ASAnna Siatouni
Anna Siatouni
ATAntonios Tavernarakis
Antonios Tavernarakis
SGStylianos Gatzonis
Stylianos Gatzonis

1 February 2012 in Asian Cardiovascular and Thoracic Annals
Verified
Journal Article
Closed access
KVKonstantinos Vachlas
Konstantinos Vachlas
CZCharalambos Zisis
Charalambos Zisis
DRDimitra Rontogianni
Dimitra Rontogianni
ATAntonios Tavernarakis
Antonios Tavernarakis
APArgini Psevdi
Argini Psevdi
IBIon Bellenis
Ion Bellenis
Myasthenia gravis is present in a significant proportion of patients with thymoma. We investigated particular features of the clinical behavior of thymoma and its relationship to myasthenia in a retrospective study of 79 patients who underwent thymectomy for thymoma during the last 20 years. The presence of myasthenia gravis, Masaoka stage, World Health Organization histotype, myasthenia response, and survival were analyzed. The mean age of the patients was 56.1 ±12.4 years, and 39 had myasthenia gravis. A significantly higher proportion of patients with myasthenia was found in B2 and B3 histotypes compared to A, AB, and B1. Among myasthenic patients, 33.3% had no response, 50% had a partial response, and 16.7% achieved complete remission. During the follow-up period, 16 (21.1%) patients died. Mean survival was 4.8 ± 1.4 years for patients with no myasthenia response, whereas those with a partial or complete myasthenia response had significantly better survival.

1 January 2004 in Journal of Neurology
Verified
Journal Article
Closed access
PDF file
CPConstantin Potagas
Constantin Potagas
GDGeorges Dellatolas
Georges Dellatolas
ATAntonios Tavernarakis
Antonios Tavernarakis
HMHelen Molari
Helen Molari
PMPolyxeni Mourtzouhou
Polyxeni Mourtzouhou
NBNikolaos Balakas
Nikolaos Balakas

1 March 2014 in Multiple Sclerosis and Related Disorders
Verified
Journal Article
Closed access
DMDimos D. Mitsikostas
Dimos D. Mitsikostas
VMVasileios Mastorodemos
Vasileios Mastorodemos
MTMinas Tsagournizakis
Minas Tsagournizakis
AKAntonios Kodounis
Antonios Kodounis
ATAntonios Tsagkaropoulos
Antonios Tsagkaropoulos
DPDimitrios Papadopoulos
Dimitrios Papadopoulos

1 May 2015 in Journal of Stroke and Cerebrovascular Diseases
Verified
Journal Article
Closed access
Panagiotis ZisPanagiotis Zis
Panagiotis Zis
PLPavlos Leivadeas
Pavlos Leivadeas
ATAntonios Tavernarakis
Antonios Tavernarakis